KNSA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -2.67%, SMA50 1.38%, SMA200 20.25%). The stock’s 14-day RSI is 47.38 (neutral), while the ATR of 2.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.46% below its high and over 138.24% above its low. Average 10-day trading volume of 550.42 thousand shares is below the 3-month average of 730.60 thousand, indicating normal recent market interest.

Kiniksa Pharmaceuticals International, plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.53. This means the shares are trading below this model’s fair value.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) closed at $78.38 USD, gaining $1.14 (1.47%) from the previous close of $77.24. The stock is currently mid-range between its 52-week high and low $35.20 and $82.94. With a market capitalization of about $5.97 billion, Kiniksa Pharmaceuticals International, plc is classified as a mid-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 748.37 thousand shares, volume is running light vs its 52-week average. Headquartered in London, GL, Kiniksa Pharmaceuticals International, plc operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Sanj K. Patel, the company employs approximately 366 people and listed since May 24, 2018. Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.

Kiniksa Pharmaceuticals International, plc has 46.30 million shares outstanding. The public float is 42.20 million shares, elevated short interest at 11.87% of float. This equals 4.51 million shares. The short ratio is 4.34 days. Institutional investors hold 106.47% of the float. Insiders own 3.58%. Cormorant Asset Management, LP holds 900.44 thousand shares, Flynn James E has 333.33 thousand shares and BAKER BROS. ADVISORS LP has 299.40 thousand shares. Over the past six months, insider transactions show net selling. They sold 169.80 thousand shares across 12 transactions.

Wall Street analysts project EPS growth of 46.7% annually over the next five years. The latest quarter delivered EPS of $0.30. The next quarter is forecast at $0.26. Next year's EPS is expected at -$146.48. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $107.00 to $44.00. The high target offers 38.53% upside. The low target suggests -43.03% downside. The mean target is $67.65. This offers -12.42% upside. Kiniksa Pharmaceuticals International, plc earnings surprise history is a mixed track record. The quarter that ended July 28, 2026, missed forecasts by -4.06%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 450.0% in April 29, 2025.

Kiniksa Pharmaceuticals International, plc trades at a P/E ratio of 72.19, slightly above the S&P 500 average, with a price-to-sales ratio of 7.0 and a price-to-book ratio of 9.16 trading at moderately above to book value. The P/FCF stands at 32.15, also above market averages.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares are flat -0.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kiniksa Pharmaceuticals International, plc trading at a premium to the broader market with a P/E of 72.19. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $53.70, suggesting -30.48% downside. Our AI forecast model points to short-term weakness (-3.47% over two weeks), a medium-term rise (22.1% over three months), and a longer-term gain (21.54% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kiniksa Pharmaceuticals International, plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.47%, with price expected at $74.56 by October 02, 2026, within a range of $73.57 to $75.62 3-Month Outlook: Projected rise of 22.1%, reaching $94.31 by December 17, 2026, with a range of $93.53 to $95.17. 1-Year Outlook: Projected gain of 21.54%, with price at $93.88 by September 17, 2027, within a range of $90.73 to $96.27.